Literature DB >> 19956427

Neuroendocrine differentiation in prostate cancer.

Yin Sun, Junyang Niu, Jiaoti Huang.   

Abstract

As any organ in the body human prostate is composed of many different types of cells as well as extracellular components. During prostate development, reciprocal cellular interactions between stromal cells and prostate epithelial cells ultimately lead to the development of a mature prostate. Normal prostate is composed of repeating cellular units that contain stromal and epithelial compartments. The epithelial compartment contains luminal epithelial cells, basal cells and a minor component of neuroendocrine cells whose function may be to regulate the growth, differentiation and secretory function of the prostate gland. Neuroendocrine cells are also evident in prostate cancer and numerous studies showed that its number increases in high grade and high stage tumors, particularly in hormonally treated and hormone-refractory (androgen-independent) prostate cancer. Although androgen withdrawal reduces the secretion of the andromedins from the prostate stromal cells that are critical for the survival for prostate epithelial cells, there is clear evidence that androgen receptor is also required for the tumorigenesis of human prostate cancer, and therefore androgen deprivation therapy likely works through inhibition of androgen receptor in the prostate epithelium. Because neuroendocrine cells lack androgen receptor and are likely androgen-independent, it is conceivable that hormonal therapy for advanced/metastatic prostate cancer, which consists of inhibiting androgen production and/or blocking androgen receptor function, will not eliminate neuroendocrine cancer cells. Instead, these cells may be enriched after the therapy and they may establish paracrine networks to stimulate androgen-independent proliferation of prostate cancer, leading to tumor recurrence. In this article, we will review the known functions of the neuroendocrine cells in prostate cancer, including stimulation of cancer proliferation and invasion, apoptosis resistance and angiogenesis as well as molecular pathways involved in neuroendocrine differentiation.

Entities:  

Keywords:  Prostate cancer; hormonal therapy; neuroendocrine

Year:  2009        PMID: 19956427      PMCID: PMC2776313     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  147 in total

1.  Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.

Authors:  J Gao; J T Arnold; J T Isaacs
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

2.  Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression.

Authors:  Xuehong Deng; Han Liu; Jiaoti Huang; Liang Cheng; Evan T Keller; Sarah J Parsons; Chang-Deng Hu
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

3.  Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention.

Authors:  Alpana Tyagi; Chapla Agarwal; Rajesh Agarwal
Journal:  Mol Cancer Ther       Date:  2002-05       Impact factor: 6.261

4.  Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation.

Authors:  Jayoung Kim; Rosalyn M Adam; Michael R Freeman
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

Review 5.  Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.

Authors:  A Berruti; L Dogliotti; A Mosca; G Gorzegno; E Bollito; M Mari; R Tarabuzzi; M Poggio; M Torta; D Fontana; A Angeli
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

6.  Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells.

Authors:  Xiu-Qing Zhang; Dmitry Kondrikov; Ta-Chun Yuan; Fen-Fen Lin; Joel Hansen; Ming-Fong Lin
Journal:  Oncogene       Date:  2003-10-02       Impact factor: 9.867

7.  Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer.

Authors:  I Sehgal; S Powers; B Huntley; G Powis; M Pittelkow; N J Maihle
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

8.  Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice.

Authors:  Barbara A Foster; Andreas Evangelou; J R Gingrich; Paula J Kaplan; Franco DeMayo; Norman M Greenberg
Journal:  Differentiation       Date:  2002-12       Impact factor: 3.880

9.  NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.

Authors:  Ren Jie Jin; Yongqing Wang; Naoya Masumori; Kenichiro Ishii; Taiji Tsukamoto; Scott B Shappell; Simon W Hayward; Susan Kasper; Robert J Matusik
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

10.  Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells.

Authors:  Beatriz Collado; Irene Gutiérrez-Cañas; Nieves Rodríguez-Henche; Juan C Prieto; María J Carmena
Journal:  Regul Pept       Date:  2004-06-15
View more
  59 in total

1.  Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer.

Authors:  Ben T Copeland; Hassan Shallal; Chentian Shen; Kenneth J Pienta; Catherine A Foss; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

Review 2.  Mouse models of prostate cancer: picking the best model for the question.

Authors:  Magdalena M Grabowska; David J DeGraff; Xiuping Yu; Ren Jie Jin; Zhenbang Chen; Alexander D Borowsky; Robert J Matusik
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

3.  Gallium-68 DOTATOC PET/CT in vivo characterization of somatostatin receptor expression in the prostate.

Authors:  Mila V Todorović-Tirnanić; Milan M Gajić; Vladimir B Obradović; Richard P Baum
Journal:  Cancer Biother Radiopharm       Date:  2014-01-22       Impact factor: 3.099

4.  Predicting clinical outcome of therapy-resistant prostate cancer.

Authors:  Xin Ma; Jiaoti Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-21       Impact factor: 11.205

5.  Interleukin-6: a bone marrow stromal cell paracrine signal that induces neuroendocrine differentiation and modulates autophagy in bone metastatic PCa cells.

Authors:  Nikki A Delk; Mary C Farach-Carson
Journal:  Autophagy       Date:  2012-04-01       Impact factor: 16.016

Review 6.  Molecular pathology of prostate cancer revealed by next-generation sequencing: opportunities for genome-based personalized therapy.

Authors:  Jiaoti Huang; Jason K Wang; Yin Sun
Journal:  Curr Opin Urol       Date:  2013-05       Impact factor: 2.309

7.  Lesson of the month 2: An unusual cause of depression in an older man: Cushing's syndrome resulting from metastatic small cell cancer of the prostate.

Authors:  Paul Kleinig; Patrick Russell
Journal:  Clin Med (Lond)       Date:  2018-10       Impact factor: 2.659

8.  Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

Authors:  Michael Ittmann; Jiaoti Huang; Enrico Radaelli; Philip Martin; Sabina Signoretti; Ruth Sullivan; Brian W Simons; Jerrold M Ward; Brian D Robinson; Gerald C Chu; Massimo Loda; George Thomas; Alexander Borowsky; Robert D Cardiff
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

9.  Evaluation of neuroendocrine markers in renal cell carcinoma.

Authors:  Hanna Ronkainen; Ylermi Soini; Markku H Vaarala; Saila Kauppila; Pasi Hirvikoski
Journal:  Diagn Pathol       Date:  2010-05-12       Impact factor: 2.644

Review 10.  The Siah2-HIF-FoxA2 axis in prostate cancer – new markers and therapeutic opportunities.

Authors:  Jianfei Qi; Maurizio Pellecchia; Ze'ev A Ronai
Journal:  Oncotarget       Date:  2010-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.